Telomerase-independent paths to immortality in predictable cancer sub-types

Journal of Cancer

Volumn 3, Issue 1, 2012, Pages 67-82

  Durant, Stephen T ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Alternative lengthening of telomeres; Cancer; DNA damage response; Immortality; Telomerase

Indexed keywords

BRCA1 PROTEIN; CHROMOSOME PROTEIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; HISTONE H2AX; MRE11 PROTEIN; NIBRIN; NUCLEASE; RAD50 PROTEIN; TELOMERASE;

ADENOCARCINOMA; ASTROCYTOMA; BLADDER CARCINOMA; BREAST CANCER; CELL LINE; CELL SURVIVAL; CHONDROSARCOMA; CHROMOSOME STRUCTURE; CLINICAL DEVELOPMENT PLAN; DNA DAMAGE; DNA END JOINING REPAIR; EMBRYO CELL; ENDOMETRIUM CARCINOMA; ENZYME ACTIVITY; ENZYME REACTIVATION; EPIGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GERM CELL TUMOR; HOMOLOGOUS RECOMBINATION; HUMAN; INTRACELLULAR SIGNALING; LARGE CELL CARCINOMA; LIVER CELL CARCINOMA; LUNG CARCINOMA; MEDULLARY CARCINOMA; MELANOMA; MESOTHELIOMA; NEPHROBLASTOMA; NEUROBLASTOMA; NONHUMAN; PAPILLARY CARCINOMA; PARAGANGLIOMA; PHENOTYPE; PREDICTION; PREVALENCE; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SACCHAROMYCES CEREVISIAE; SARCOMA; SISTER CHROMATID EXCHANGE; SMALL CELL SARCOMA; SOFT TISSUE SARCOMA; SOMATIC CELL; STOMACH CARCINOMA; TELOMERE HOMEOSTASIS; TELOMERE SHORTENING; TESTIS CANCER; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA;

EID: 84862514686     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.3965     Document Type: Review

References (140)

1. Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, et al. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc.Natl.Acad.Sci.U.S.A. 1988 Sep;85(18):6622-6626.
2. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, et al. Mammalian telomeres end in a large duplex loop. Cell 1999 May 14;97(4):503-514.
3. Vaziri H, Benchimol S. From telomere loss to p53 induction and activation of a DNA-damage pathway at senescence: the telomere loss/DNA damage model of cell aging. Exp.Gerontol. 1996;31(1-2):295-301.
4. Shay JW, Wright WE. Telomerase activity in human cancer. Curr.Opin.Oncol. 1996 Jan;8(1):66-71.
5. Harley CB. Telomere loss: mitotic clock or genetic time bomb? Mutat.Res. 1991;256(2-6):271-282.
6. Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdorp PM. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc.Natl.Acad.Sci.U.S.A. 1994 Oct 11;91(21):9857-9860.
7. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003 Nov 13;426(6963):194-198.
8. Blackburn EH, Greider CW, Henderson E, Lee MS, Shampay J, Shippen-Lentz D. Recognition and elongation of telomeres by telomerase. Genome 1989;31(2):553-560.
9. Cesare AJ, Reddel RR. Telomere uncapping and alternative lengthening of telomeres. Mech. Ageing Dev. 2008;129(1-2):99-108.
10. Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and implications. Nat.Rev.Genet. 2010 May;11(5):319-330.
11. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline and embryonic tissues and cells. Dev.Genet. 1996;18(2):173-179.
12. Ulaner GA, Giudice LC. Developmental regulation of telomerase activity in human fetal tissues during gestation. Mol.Hum.Reprod. 1997 Sep;3(9):769-773.
13. Reddel RR, Bryan TM, Colgin LM, Perrem KT, Yeager TR. Alternative lengthening of telomeres in human cells. Radiat.Res. 2001 Jan;155(1 Pt 2):194-200.
14. Henson JD, Hannay JA, McCarthy SW, Royds JA, Yeager TR, Robinson RA, et al. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin. Cancer Res. 2005 Jan 1;11(1):217-225.
15. Shay JW, Wright WE. The reactivation of telomerase activity in cancer progression. Trends Genet. 1996 Apr;12(4):129-131.
16. Holt SE, Wright WE, Shay JW. Regulation of telomerase activity in immortal cell lines. Mol.Cell.Biol. 1996 Jun;16(6):2932-2939.
17. Molckovsky A, Siu LL. First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J.Hematol.Oncol. 2008 Oct 29;1:20.
18. Roth A, Harley CB, Baerlocher GM. Imetelstat (GRN163L)-telomerase-based cancer therapy. Recent Results Cancer Res. 2010;184:221-234.
19. Ouellette MM, Wright WE, Shay JW. Targeting telomerase-expressing cancer cells. J.Cell.Mol.Med. 2011 Jul;15(7):1433-1442.
20. Buseman CM, Wright WE, Shay JW. Is telomerase a viable target in cancer? Mutat.Res. 2012 Feb 1;730(1-2):90-7.
21. Ouellette MM, Wright WE, Shay JW. Targeting telomerase-expressing cancer cells. J.Cell.Mol.Med. 2011 Jul;15(7):1433-1442.
22. Sidorov IA, Hirsch KS, Harley CB, Dimitrov DS. Cancer treatment by telomerase inhibitors: predictions by a kinetic model. Math.Biosci. 2003 Feb;181(2):209-221.
23. Folini M, Gandellini P, Zaffaroni N. Targeting the telosome: therapeutic implications. Biochim.Biophys. Acta 2009 Apr;1792(4):309-316.
24. Siddiqa A, Cavazos DA, Marciniak RA. Targeting telomerase. Rejuvenation Res. 2006;9(3):378-390.
25. Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and implications. Nat.Rev.Genet. 2010 May;11(5):319-330.
26. Royle NJ, Mendez-Bermudez A, Gravani A, Novo C, Foxon J, Williams J, et al. The role of recombination in telomere length maintenance. Biochem.Soc.Trans. 2009 Jun;37(Pt 3):589-595.
27. Saharia A, Stewart SA. FEN1 contributes to telomere stability in ALT-positive tumor cells. Oncogene 2009 Feb 26;28(8):1162-1167.
28. Zeng S, Yang Q. The MUS81 endonuclease is essential for telomerase negative cell proliferation. Cell. Cycle 2009 Jul 15;8(14):2157-2160.
29. Zeng S, Xiang T, Pandita TK, Gonzalez-Suarez I, Gonzalo S, Harris CC, et al. Telomere recombination requires the MUS81 endonuclease. Nat. Cell Biol. 2009 May;11(5):616-623.
30. Temime-Smaali N, Guittat L, Sidibe A, Shin-ya K, Trentesaux C, Riou JF. The G-quadruplex ligand telomestatin impairs binding of topoisomerase IIIalpha to G-quadruplex-forming oligonucleotides and uncaps telomeres in ALT cells. PLoS One 2009 Sep 9;4(9):e6919.
31. Patel DJ, Phan AT, Kuryavyi V. Human telomere, oncogenic promoter and 5'-UTR G-quadruplexes: diverse higher order DNA and RNA targets for cancer therapeutics. Nucleic Acids Res. 2007;35(22):7429-7455.
32. Huppert JL, Balasubramanian S. G-quadruplexes in promoters throughout the human genome. Nucleic Acids Res. 2007;35(2):406-413.
33. Huppert JL. Four-stranded nucleic acids: structure, function and targeting of G-quadruplexes. Chem.Soc.Rev. 2008 Jul;37(7):1375-1384.
34. Huppert JL. Structure, location and interactions of G-quadruplexes. FEBS J. 2010 Sep;277(17):3452-3458.
35. Cerone MA, Londono-Vallejo JA, Bacchetti S. Telomere maintenance by telomerase and by recombination can coexist in human cells. Hum.Mol.Genet. 2001 Sep 1;10(18):1945-1952.
36. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat.Med. 1995 Mar;1(3):249-255.
37. Hiyama E, Hiyama K, Nishiyama M, Reynolds CP, Shay JW, Yokoyama T. Differential gene expression profiles between neuroblastomas with high telomerase activity and low te-lomerase activity. J.Pediatr.Surg. 2003 Dec;38(12):1730-1734.
38. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telo-mere elongation in immortal human cells without detectable telomerase activity. EMBO J. 1995 Sep 1;14(17):4240-4248.
39. Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res. 1999 Sep 1;59(17):4175-4179.
40. Henson JD, Reddel RR. Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers. FEBS Lett. 2010 Sep 10;584(17):3800-3811.
41. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985 Dec;43(2 Pt 1):405-413.
42. Greider CW, Blackburn EH. The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell 1987 Dec 24;51(6):887-898.
43. Greider CW, Blackburn EH. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature 1989 Jan 26;337(6205):331-337.
44. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994 Dec 23;266(5193):2011-2015.
45. Xin H. Telomeric repeat amplification protocol: measuring the activity of the telomerase. Methods Mol.Biol. 2011;735:107-111.
46. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011 Jul 22;333(6041):425.
47. Lundblad V, Blackburn EH. An alternative pathway for yeast telomere maintenance rescues est1- senescence. Cell 1993 Apr 23;73(2):347-360.
48. Teng SC, Zakian VA. Telomere-telomere recombination is an efficient bypass pathway for telomere maintenance in Saccharomyces cerevisiae. Mol.Cell.Biol. 1999 Dec;19(12):8083-8093.
49. Dunham MA, Neumann AA, Fasching CL, Reddel RR. Telomere maintenance by recombination in human cells. Nat.Genet. 2000 Dec;26(4):447-450.
50. Bailey SM, Brenneman MA, Goodwin EH. Frequent recombination in telomeric DNA may extend the proliferative life of telomerase-negative cells. Nucleic Acids Res. 2004 Jul 16;32(12):3743-3751.
51. Royle NJ, Foxon J, Jeyapalan JN, Mendez-Bermudez A, Novo CL, Williams J, et al. Telomere length maintenance-an ALTernative mechanism. Cytogenet. Genome Res. 2008;122(3-4):281-291.
52. Pickett HA, Henson JD, Au AY, Neumann AA, Reddel RR. Normal mammalian cells negatively regulate telomere length by telomere trimming. Hum.Mol.Genet. 2011 Dec 1;20(23):4684-4692.
53. Verdun RE, Crabbe L, Haggblom C, Karlseder J. Functional human telomeres are recognized as DNA damage in G2 of the cell cycle. Mol. Cell 2005 Nov 23;20(4):551-561.
54. De Boeck G, Forsyth RG, Praet M, Hogendoorn PC. Telomere-associated proteins: cross-talk between telomere maintenance and telomere-lengthening mechanisms. J.Pathol. 2009 Feb;217(3):327-344.
55. Durant ST, Paffett KS, Shrivastav M, Timmins GS, Morgan WF, Nickoloff JA. UV radiation induces delayed hyperrecombination associated with hypermutation in human cells. Mol.Cell.Biol. 2006 Aug;26(16):6047-6055.
56. Tanaka H, Mendonca MS, Bradshaw PS, Hoelz DJ, Malkas LH, Meyn MS, et al. DNA damage-induced phosphorylation of the human telomere-associated protein TRF2. Proc.Natl.Acad.Sci.U.S.A. 2005 Oct 25;102(43):15539-15544.
57. Huda N, Tanaka H, Mendonca MS, Gilley D. DNA damage-induced phosphorylation of TRF2 is required for the fast pathway of DNA double-strand break repair. Mol.Cell.Biol. 2009 Jul;29(13):3597-3604.
58. Vousden KH, Lane DP. P53 in Health and Disease. Nat.Rev.Mol. Cell Biol. 2007 Apr;8(4):275-283.
59. Jansson M, Durant ST, Cho EC, Sheahan S, Edelmann M, Kessler B, et al. Arginine methylation regulates the p53 response. Nat. Cell Biol. 2008 Dec;10(12):1431-1439.
60. Durant ST, Cho EC, La Thangue NB. p53 methylation-the Arg-ument is clear. Cell. Cycle 2009 Mar 15;8(6):801-802.
61. Vaziri H, West MD, Allsopp RC, Davison TS, Wu YS, Arrowsmith CH, et al. ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase. EMBO J. 1997 Oct 1;16(19):6018-6033.
62. Dantzer F, Giraud-Panis MJ, Jaco I, Ame JC, Schultz I, Blasco M, et al. Functional interaction between poly(ADP-Ribose) polymerase 2 (PARP-2) and TRF2: PARP activity negatively regulates TRF2. Mol.Cell.Biol. 2004 Feb;24(4):1595-1607.
63. Jiang WQ, Zhong ZH, Henson JD, Neumann AA, Chang AC, Reddel RR. Suppression of alternative lengthening of telomeres by Sp100-mediated sequestration of the MRE11/RAD50/NBS1 complex. Mol.Cell.Biol. 2005 Apr;25(7):2708-2721.
64. Lee JH, Paull TT. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 2007 Dec 10;26(56):7741-7748.
65. Wu Y, Xiao S, Zhu XD. MRE11-RAD50-NBS1 and ATM function as co-mediators of TRF1 in telomere length control. Nat.Struct.Mol.Biol. 2007 Sep;14(9):832-840.
66. Zhong ZH, Jiang WQ, Cesare AJ, Neumann AA, Wadhwa R, Reddel RR. Disruption of telomere maintenance by depletion of the MRE11/RAD50/NBS1 complex in cells that use alternative lengthening of telomeres. J.Biol.Chem. 2007 Oct 5;282(40):29314-29322.
67. Celli GB, Denchi EL, de Lange T. Ku70 stimulates fusion of dysfunctional telomeres yet protects chromosome ends from homologous recombination. Nat. Cell Biol. 2006 Aug;8(8):885-890.
68. Bodvarsdottir SK, Steinarsdottir M, Bjarnason H, Eyfjord JE. Dysfunctional telomeres in human BRCA2 mutated breast tumors and cell lines. Mutat.Res. 2012 Jan 3;729(1-2):90-9.
69. French JD, Dunn J, Smart CE, Manning N, Brown MA. Disruption of BRCA1 function results in telomere lengthening and increased anaphase bridge formation in immortalized cell lines. Genes Chromosomes Cancer 2006 Mar;45(3):277-289.
70. Li B, Reddy S, Comai L. Depletion of Ku70/80 reduces the levels of extrachromosomal telomeric circles and inhibits proliferation of ALT cells. Aging (Albany NY) 2011 Apr;3(4):395-406.
71. Liu Y, Tarsounas M, O'regan P, West SC. Role of RAD51C and XRCC3 in genetic recombination and DNA repair. J.Biol.Chem. 2007 Jan 19;282(3):1973-1979.
72. Ding H, Schertzer M, Wu X, Gertsenstein M, Selig S, Kammori M, et al. Regulation of murine telomere length by Rtel: an essential gene encoding a helicase-like protein. Cell 2004 Jun 25;117(7):873-886.
73. Durant ST, Nickoloff JA. Good timing in the cell cycle for precise DNA repair by BRCA1. Cell. Cycle 2005 Sep;4(9):1216-1222.
74. Durant ST, Paffett KS, Shrivastav M, Timmins GS, Morgan WF, Nickoloff JA. UV radiation induces delayed hyperrecombination associated with hypermutation in human cells. Mol.Cell.Biol. 2006 Aug;26(16):6047-6055.
75. Shrivastav M, Miller CA, De Haro LP, Durant ST, Chen BP, Chen DJ, et al. DNA-PKcs and ATM co-regulate DNA double-strand break repair. DNA Repair (Amst) 2009 Aug 6;8(8):920-929.
76. Lee SH, Oshige M, Durant ST, Rasila KK, Williamson EA, Ramsey H, et al. The SET domain protein Metnase mediates foreign DNA integration and links integration to nonhomologous end-joining repair. Proc.Natl.Acad.Sci.U.S.A. 2005 Dec 13;102(50):18075-18080.
77. De Haro LP, Wray J, Williamson EA, Durant ST, Corwin L, Gentry AC, et al. Metnase promotes restart and repair of stalled and collapsed replication forks. Nucleic Acids Res. 2010 Sep;38(17):5681-5691.
78. MacKay C, Declais AC, Lundin C, Agostinho A, Deans AJ, MacArtney TJ, et al. Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by monoubiquitinated FANCD2. Cell 2010 Jul 9;142(1):65-76.
79. Yamamoto KN, Kobayashi S, Tsuda M, Kurumizaka H, Takata M, Kono K, et al. Involvement of SLX4 in interstrand cross-link repair is regulated by the Fanconi anemia pathway. Proc.Natl.Acad.Sci.U.S.A. 2011 Apr 19;108(16):6492-6496.
80. Zhu XD, Niedernhofer L, Kuster B, Mann M, Hoeijmakers JH, de Lange T. ERCC1/XPF removes the 3' overhang from uncapped telomeres and represses formation of telomeric DNA-containing double minute chromosomes. Mol. Cell 2003 Dec;12(6):1489-1498.
81. Chen XB, Melchionna R, Denis CM, Gaillard PH, Blasina A, Van de Weyer I, et al. Human Mus81-associated endonuclease cleaves Holliday junctions in vitro. Mol. Cell 2001 Nov;8(5):1117-1127.
82. Boddy MN, Gaillard PH, McDonald WH, Shanahan P, Yates JR,3rd, Russell P. Mus81-Eme1 are essential components of a Holliday junction resolvase. Cell 2001 Nov 16;107(4):537-548.
83. Osman F, Whitby MC. Exploring the roles of Mus81-Eme1/Mms4 at perturbed replication forks. DNA Repair (Amst) 2007 Jul 1;6(7):1004-1017.
84. Tsutakawa SE, Classen S, Chapados BR, Arvai AS, Finger LD, Guenther G, et al. Human flap endonuclease structures, DNA double-base flipping, and a unified understanding of the FEN1 superfamily. Cell 2011 Apr 15;145(2):198-211.
85. Zheng L, Shen B. Okazaki fragment maturation: nucleases take centre stage. J.Mol.Cell.Biol. 2011 Feb;3(1):23-30.
86. Liu Y, Kao HI, Bambara RA. Flap endonuclease 1: a central component of DNA metabolism. Annu.Rev.Biochem. 2004;73:589-615.
87. Crabbe L, Verdun RE, Haggblom CI, Karlseder J. Defective telomere lagging strand synthesis in cells lacking WRN helicase activity. Science 2004 Dec 10;306(5703):1951-1953.
88. Eller MS, Liao X, Liu S, Hanna K, Backvall H, Opresko PL, et al. A role for WRN in telomere-based DNA damage responses. Proc.Natl.Acad.Sci.U.S.A. 2006 Oct 10;103(41):15073-15078.
89. Opresko PL, Sowd G, Wang H. The Werner syndrome helicase/exonuclease processes mobile D-loops through branch migration and degradation. PLoS One 2009;4(3):e4825.
90. Kusumoto-Matsuo R, Opresko PL, Ramsden D, Tahara H, Bohr VA. Cooperation of DNA-PKcs and WRN helicase in the maintenance of telomeric D-loops. Aging (Albany NY) 2010 May;2(5):274-284.
91. Laud PR, Multani AS, Bailey SM, Wu L, Ma J, Kingsley C, et al. Elevated telomere-telomere recombination in WRN-deficient, telomere dysfunctional cells promotes escape from senescence and engagement of the ALT pathway. Genes Dev. 2005 Nov 1;19(21):2560-2570.
92. Noel JF, Wellinger RJ. The Smc5/6 complex and the difficulties cutting the ties of twin sisters. Aging (Albany NY) 2011 Mar;3(3):186-188.
93. Potts PR, Yu H. The SMC5/6 complex maintains telomere length in ALT cancer cells through SUMOylation of telomere-binding proteins. Nat.Struct.Mol.Biol. 2007 Jul;14(7):581-590.
94. Chavez A, George V, Agrawal V, Johnson FB. Sumoylation and the structural maintenance of chromosomes (Smc) 5/6 complex slow senescence through recombination intermediate resolution. J.Biol.Chem. 2010 Apr 16;285(16):11922-11930.
95. Grewal SI, Jia S. Heterochromatin revisited. Nat.Rev.Genet. 2007 Jan;8(1):35-46.
96. Nguyen AT, Zhang Y. The diverse functions of Dot1 and H3K79 methylation. Genes Dev. 2011 Jul 1;25(13):1345-1358.
97. Norris A, Boeke JD. Silent information regulator 3: the Goldi-locks of the silencing complex. Genes Dev. 2010 Jan 15;24(2):115-122.
98. Gonzalo S, Jaco I, Fraga MF, Chen T, Li E, Esteller M, et al. DNA methyltransferases control telomere length and telomere recombination in mammalian cells. Nat. Cell Biol. 2006 Apr;8(4):416-424.
99. Oberdoerffer P, Michan S, McVay M, Mostoslavsky R, Vann J, Park SK, et al. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell 2008 Nov 28;135(5):907-918.
100. Vaitiekunaite R, Butkiewicz D, Krzesniak M, Przybylek M, Gryc A, Snietura M, et al. Expression and localization of Werner syndrome protein is modulated by SIRT1 and PML. Mech. Ageing Dev. 2007;128(11-12):650-661.
101. Kahyo T, Mostoslavsky R, Goto M, Setou M. Sirtuin-mediated deacetylation pathway stabilizes Werner syndrome protein. FEBS Lett. 2008 Jul 23;582(17):2479-2483.
102. Sakao Y, Kato A, Tsuji T, Yasuda H, Togawa A, Fujigaki Y, et al. Cisplatin induces Sirt1 in association with histone deacetylation and increased Werner syndrome protein in the kidney. Clin.Exp.Nephrol. 2011 Jun;15(3):363-372.
103. Yuan Z, Zhang X, Sengupta N, Lane WS, Seto E. SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol. Cell 2007 Jul 6;27(1):149-162.
104. Yuan Z, Seto E. A functional link between SIRT1 deacetylase and NBS1 in DNA damage response. Cell. Cycle 2007 Dec 1;6(23):2869-2871.
105. Lim DS, Kim ST, Xu B, Maser RS, Lin J, Petrini JH, et al. ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature 2000 Apr 6;404(6778):613-617.
106. Palacios JA, Herranz D, De Bonis ML, Velasco S, Serrano M, Blasco MA. SIRT1 contributes to telomere maintenance and augments global homologous recombination. J. Cell Biol. 2010 Dec 27;191(7):1299-1313.
107. Law MJ, Lower KM, Voon HP, Hughes JR, Garrick D, Viprakasit V, et al. ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner. Cell 2010 Oct 29;143(3):367-378.
108. Goldberg AD, Banaszynski LA, Noh KM, Lewis PW, Elsaesser SJ, Stadler S, et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 2010 Mar 5;140(5):678-691.
109. Wong LH, McGhie JD, Sim M, Anderson MA, Ahn S, Hannan RD, et al. ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. Genome Res. 2010 Mar;20(3):351-360.
110. Lafferty-Whyte K, Cairney CJ, Will MB, Serakinci N, Daidone MG, Zaffaroni N, et al. A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT. Oncogene 2009 Oct 29;28(43):3765-3774.
111. Xue Y, Li L, Zhang D, Wu K, Chen Y, Zeng J, et al. Twisted Epithelial-to-Mesenchymal Transition Promotes Progression of Surviving Bladder Cancer T24 Cells with hTERT-Dysfunction. PLoS One 2011;6(11):e27748.
112. Stiller D, Path FW, Kaiser HE. Some characteristics of the mesenchymal stem cell of soft tissue tumors. In Vivo 1992;6(4):477-480.
113. Atkinson SP, Hoare SF, Glasspool RM, Keith WN. Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters. Cancer Res. 2005 Sep 1;65(17):7585-7590.
114. Lafferty-Whyte K, Cairney CJ, Will MB, Serakinci N, Daidone MG, Zaffaroni N, et al. A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT. Oncogene 2009 Oct 29;28(43):3765-3774.
115. Hao H, Nancai Y, Lei F, Xiong W, Wen S, Guofu H, et al. siRNA directed against c-Myc inhibits proliferation and downregulates human telomerase reverse transcriptase in human colon cancer Colo 320 cells. J.Exp.Clin. Cancer Res. 2008 Aug 12;27:27.
116. Chang M, Dittmar JC, Rothstein R. Long telomeres are preferentially extended during recombination-mediated telomere maintenance. Nat.Struct.Mol.Biol. 2011 Apr;18(4):451-456.
117. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011 Jul 22;333(6041):425.
118. McDonald KL, McDonnell J, Muntoni A, Henson JD, Hegi ME, von Deimling A, et al. Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival. J.Neuropathol.Exp.Neurol. 2010 Jul;69(7):729-736.
119. Costa A, Daidone MG, Daprai L, Villa R, Cantu S, Pilotti S, et al. Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res. 2006 Sep 1;66(17):8918-8924.
120. Henson JD, Neumann AA, Yeager TR, Reddel RR. Alternative lengthening of telomeres in mammalian cells. Oncogene 2002 Jan 21;21(4):598-610.
121. Villa R, Daidone MG, Motta R, Venturini L, De Marco C, Vannelli A, et al. Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. Clin. Cancer Res. 2008 Jul 1;14(13):4134-4140.
122. Subhawong AP, Heaphy CM, Argani P, Konishi Y, Kouprina N, Nassar H, et al. The alternative lengthening of telomeres phenotype in breast carcinoma is associated with HER-2 overexpression. Mod.Pathol. 2009 Nov;22(11):1423-1431.
123. Venturini L, Erdas R, Costa A, Gronchi A, Pilotti S, Zaffaroni N, et al. ALT-associated promyelocytic leukaemia body (APB) detection as a reproducible tool to assess alternative lengthening of telomere stability in liposarcomas. J.Pathol. 2008 Mar;214(4):410-414.
124. Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E, et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am.J.Pathol. 2011 Oct;179(4):1608-1615.
125. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011 Jul 22;333(6041):425.
126. Silvestre DC, Pineda JR, Hoffschir F, Studler JM, Mouthon MA, Pflumio F, et al. Alternative lengthening of telomeres in human glioma stem cells. Stem Cells 2011 Mar;29(3):440-451.
127. Lundberg G, Sehic D, Lansberg JK, Ora I, Frigyesi A, Castel V, et al. Alternative lengthening of telomeres-an enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas. Genes Chromosomes Cancer 2011 Apr;50(4):250-262.
128. Au AY, Hackl T, Yeager TR, Cohen SB, Pass HI, Harris CC, et al. Telomerase activity in pleural malignant mesotheliomas. Lung Cancer 2011 Sep;73(3):283-288.
129. Lundberg G, Sehic D, Lansberg JK, Ora I, Frigyesi A, Castel V, et al. Alternative lengthening of telomeres-an enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas. Genes Chromosomes Cancer 2011 Apr;50(4):250-262.
130. Venturini L, Motta R, Gronchi A, Daidone M, Zaffaroni N. Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. BMC Cancer 2010 Jun 3;10:254.
131. Henson JD, Reddel RR. Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers. FEBS Lett. 2010 Sep 10;584(17):3800-3811.
132. Slatter T, Gifford-Garner J, Wiles A, Tan X, Chen YJ, MacFarlane M, et al. Pilocytic astrocytomas have telomere-associated promyelocytic leukemia bodies without alternatively lengthened telomeres. Am.J.Pathol. 2010 Dec;177(6):2694-2700.
133. Matsuo T, Shimose S, Kubo T, Fujimori J, Yasunaga Y, Ochi M. Alternative lengthening of telomeres as a prognostic factor in malignant fibrous histiocytomas of bone. Anticancer Res. 2010 Dec;30(12):4959-4962.
134. Yamamoto Y, Yamamoto N, Tajima K, Ohno A, Washimi Y, Ishimura D, et al. Characterization of human multicentric osteosarcoma using newly established cells derived from multicentric osteosarcoma. J. Cancer Res.Clin.Oncol. 2011 Mar;137(3):423-433.
135. Lundberg G, Sehic D, Lansberg JK, Ora I, Frigyesi A, Castel V, et al. Alternative lengthening of telomeres-An enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas. Genes Chromosomes Cancer 2011 Apr;50(4):250-62.
136. Omori Y, Nakayama F, Li D, Kanemitsu K, Semba S, Ito A, et al. Alternative lengthening of telomeres frequently occurs in mismatch repair system-deficient gastric carcinoma. Cancer.Sci. 2009 Mar;100(3):413-418.
137. Venturini L, Daidone MG, Motta R, Collini P, Spreafico F, Terenziani M, et al. Telomere maintenance in Wilms tumors: first evidence for the presence of alternative lengthening of telomeres mechanism. Genes Chromosomes Cancer 2011 Oct;50(10):823-829.
138. Dome JS, Chung S, Bergemann T, Umbricht CB, Saji M, Carey LA, et al. High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor. Cancer Res. 1999 Sep 1;59(17):4301-4307.
139. Dome JS, Bockhold CA, Li SM, Baker SD, Green DM, Perlman EJ, et al. High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms' tumor. J.Clin.Oncol. 2005 Dec 20;23(36):9138-9145.
140. Wittmann S, Wunder C, Zirn B, Furtwangler R, Wegert J, Graf N, et al. New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors. Genes Chromosomes Cancer 2008 May;47(5):386-395.